PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1320981-8	1992	We deduce from our pharmacological analysis that the early phase contains a putative alpha 1B-adrenoceptor component (susceptible to CEC or prazosin but not to nifedipine) and a P2-purinoceptor component (susceptible to suramin or nifedipine) whereas the plateau phase contains an alpha 1A-adrenoceptor component (susceptible to prazosin or nifedipine but not to CEC) and a P2-purinoceptor component (susceptible to suramin or nifedipine).	Prazosin	140-148	adrenoceptor alpha 1B	Rattus norvegicus	85-106	
18702011-10	2008	Our data show that prazosin, but not naftopidil, causes differential alterations in NOS levels in the SHR genitourinary tract, which could be due to increased pelvic blood flow resulting from inhibiting the vascular alpha(1B)-adrenoceptor.	Prazosin	19-27	adrenoceptor alpha 1B	Rattus norvegicus	216-238	
7906656-4	1993	Pretreatment of the tubules with chloroethylclonidine, 100 microM, reduced the Bmax of [3H]prazosin binding by about 50%, indicating the presence of the alpha 1B-adrenoceptor subtype.	Prazosin	91-99	adrenoceptor alpha 1B	Rattus norvegicus	153-174	
8264553-2	1993	Treatment with chloroethylclonidine (10 microM, for 30 min at 37 degrees, with subsequent washout) abolished [3H]prazosin binding to alpha 1B-adrenoceptors in rat spleen almost completely and reduced specific binding in rat kidney and cerebral cortex by a percentage comparable to the known alpha 1B-adrenoceptor content of these tissues.	Prazosin	113-121	adrenoceptor alpha 1B	Rattus norvegicus	133-154	
7687719-4	1993	Pretreatment of ventricular heart membranes with the irreversible alpha 1B-adrenoceptor-selective antagonist chloroethylclonidine resulted in the same percentage of loss of specific [3H]prazosin binding in both groups of rats.	Prazosin	186-194	adrenoceptor alpha 1B	Rattus norvegicus	66-87